Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

Nicholas A, Meanwell; John F, Kadow

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2007

Data sources: Europe PubMed Central

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

descriptionPublicationkeyboard_double_arrow_right Article 27 Nov 2007 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 8 (issn: 1472-4472,

Copyright policy )

Authors: Nicholas A, Meanwell; John F, Kadow;

pmid: 17668369

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

- Summary
- Subjects
- Metrics

Abstract

Pfizer Inc is developing maraviroc, a CCR5 receptor antagonist for the treatment of HIV-1 infection and rheumatoid arthritis. In April 2007, the FDA advisory committee voted to approve maraviroc for HIV-1 infection. Phase II and III clinical trials, and post-approval studies are ongoing in both treatment-experienced and -naive HIV patients. Phase II trials have also been initiated in patients with rheumatoid arthritis.

Keywords

Acquired Immunodeficiency Syndrome, Receptors, CCR5, Anti-HIV Agents, Anti-Inflammatory Agents, HIV Infections, Triazoles, Arthritis, Rheumatoid, Maraviroc, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Cyclohexanes, CCR5 Receptor Antagonists, Animals, Humans

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	48
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%